Is ZURA or ZBIO more profitable?

Zura Bio's return on equity of -56.13% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -56.13% -50.15% Zenas BioPharma N/A -122.45% -58.04%

Does the media refer more to ZURA or ZBIO?

In the previous week, Zura Bio and Zura Bio both had 1 articles in the media. Zenas BioPharma's average media sentiment score of 1.72 beat Zura Bio's score of 0.80 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings & valuation, ADMA or ZURA?

ADMA Biologics has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADMA Biologics $510.17M 4.21 $146.93M $0.70 13.69 Zura Bio N/A N/A -$99.35M -$1.13 N/A

Is ADMA or ZURA more profitable?

ADMA Biologics has a net margin of 32.98% compared to Zura Bio's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets ADMA Biologics 32.98% 40.17% 26.97% Zura Bio N/A -56.13% -50.15%

Does the media favor ADMA or ZURA?

In the previous week, ADMA Biologics had 5 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for ADMA Biologics and 1 mentions for Zura Bio. ADMA Biologics' average media sentiment score of 1.31 beat Zura Bio's score of 0.80 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ZURA or ZYME?

Zymeworks has higher revenue and earnings than Zura Bio. Zymeworks is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.13 N/A Zymeworks $105.96M 20.02 -$81.13M -$2.02 N/A

Is ZURA or ZYME more profitable?

Zura Bio has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Zura Bio's return on equity of -56.13% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -56.13% -50.15% Zymeworks -405.31% -72.30% -37.18%

Does the media prefer ZURA or ZYME?

In the previous week, Zymeworks had 18 more articles in the media than Zura Bio. MarketBeat recorded 19 mentions for Zymeworks and 1 mentions for Zura Bio. Zymeworks' average media sentiment score of 0.88 beat Zura Bio's score of 0.80 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, NBTX or ZURA?

Nanobiotix has higher revenue and earnings than Zura Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 54.92 -$27.11M N/A N/A Zura Bio N/A N/A -$99.35M -$1.13 N/A

Is NBTX or ZURA more profitable?

Nanobiotix's return on equity of 0.00% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Zura Bio N/A -56.13% -50.15%

Does the media favor NBTX or ZURA?

In the previous week, Nanobiotix had 2 more articles in the media than Zura Bio. MarketBeat recorded 3 mentions for Nanobiotix and 1 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.80 beat Nanobiotix's score of 0.75 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ZURA or VCEL?

Vericel has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.13 N/A Vericel $306.30M 6.77 $16.52M $0.47 86.11

Is ZURA or VCEL more profitable?

Vericel has a net margin of 7.91% compared to Zura Bio's net margin of 0.00%. Vericel's return on equity of 6.91% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -56.13% -50.15% Vericel 7.91% 6.91% 5.02%

Does the media refer more to ZURA or VCEL?

In the previous week, Vericel had 4 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Vericel and 1 mentions for Zura Bio. Vericel's average media sentiment score of 1.69 beat Zura Bio's score of 0.80 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Zura Bio (ZURA) Competitors

$5.88 +0.21 (+3.70%)

As of 04:00 PM Eastern

Compare

ZURA vs. ZBIO, ADMA, ZYME, NBTX, and VCEL

Should you buy Zura Bio stock or one of its competitors? Zura Bio's main competitors and comparable companies include Zenas BioPharma (ZBIO), ADMA Biologics (ADMA), Zymeworks (ZYME), Nanobiotix (NBTX), and Vericel (VCEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zura Bio compare to Zenas BioPharma?

Zura Bio (NASDAQ:ZURA) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Zura Bio has higher earnings, but lower revenue than Zenas BioPharma. Zura Bio is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A
Zenas BioPharma	$10M	214.57	-$377.74M	-$8.99	N/A

Zura Bio has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.04, suggesting that its share price is 204% less volatile than the broader market.

Zura Bio's return on equity of -56.13% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
Zenas BioPharma	N/A	-122.45%	-58.04%

Zura Bio currently has a consensus target price of $17.00, suggesting a potential upside of 189.12%. Zenas BioPharma has a consensus target price of $45.71, suggesting a potential upside of 38.86%. Given Zura Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Zura Bio is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Zura Bio and Zura Bio both had 1 articles in the media. Zenas BioPharma's average media sentiment score of 1.72 beat Zura Bio's score of 0.80 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

61.1% of Zura Bio shares are held by institutional investors. 12.4% of Zura Bio shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Zura Bio beats Zenas BioPharma on 9 of the 14 factors compared between the two stocks.

How does Zura Bio compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Zura Bio (NASDAQ:ZURA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

ADMA Biologics has a net margin of 32.98% compared to Zura Bio's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Zura Bio	N/A	-56.13%	-50.15%

ADMA Biologics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

In the previous week, ADMA Biologics had 5 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for ADMA Biologics and 1 mentions for Zura Bio. ADMA Biologics' average media sentiment score of 1.31 beat Zura Bio's score of 0.80 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 12.4% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ADMA Biologics has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.21	$146.93M	$0.70	13.69
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A

ADMA Biologics currently has a consensus target price of $18.67, suggesting a potential upside of 94.85%. Zura Bio has a consensus target price of $17.00, suggesting a potential upside of 189.12%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts clearly believe Zura Bio is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

ADMA Biologics beats Zura Bio on 11 of the 16 factors compared between the two stocks.

How does Zura Bio compare to Zymeworks?

Zura Bio (NASDAQ:ZURA) and Zymeworks (NASDAQ:ZYME) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Zura Bio currently has a consensus target price of $17.00, suggesting a potential upside of 189.12%. Zymeworks has a consensus target price of $40.00, suggesting a potential upside of 33.78%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Zura Bio has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zymeworks has higher revenue and earnings than Zura Bio. Zymeworks is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A
Zymeworks	$105.96M	20.02	-$81.13M	-$2.02	N/A

Zura Bio has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Zura Bio's return on equity of -56.13% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
Zymeworks	-405.31%	-72.30%	-37.18%

In the previous week, Zymeworks had 18 more articles in the media than Zura Bio. MarketBeat recorded 19 mentions for Zymeworks and 1 mentions for Zura Bio. Zymeworks' average media sentiment score of 0.88 beat Zura Bio's score of 0.80 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zymeworks beats Zura Bio on 9 of the 16 factors compared between the two stocks.

How does Zura Bio compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Zura Bio (NASDAQ:ZURA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Nanobiotix has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market.

Nanobiotix has higher revenue and earnings than Zura Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	54.92	-$27.11M	N/A	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A

In the previous week, Nanobiotix had 2 more articles in the media than Zura Bio. MarketBeat recorded 3 mentions for Nanobiotix and 1 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.80 beat Nanobiotix's score of 0.75 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nanobiotix's return on equity of 0.00% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Zura Bio	N/A	-56.13%	-50.15%

Nanobiotix presently has a consensus price target of $37.33, suggesting a potential downside of 6.67%. Zura Bio has a consensus price target of $17.00, suggesting a potential upside of 189.12%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Zura Bio beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

How does Zura Bio compare to Vericel?

Zura Bio (NASDAQ:ZURA) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Zura Bio has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, Vericel has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Vericel has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A
Vericel	$306.30M	6.77	$16.52M	$0.47	86.11

61.1% of Zura Bio shares are held by institutional investors. 12.4% of Zura Bio shares are held by insiders. Comparatively, 7.6% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Vericel had 4 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Vericel and 1 mentions for Zura Bio. Vericel's average media sentiment score of 1.69 beat Zura Bio's score of 0.80 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Vericel has a net margin of 7.91% compared to Zura Bio's net margin of 0.00%. Vericel's return on equity of 6.91% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
Vericel	7.91%	6.91%	5.02%

Zura Bio currently has a consensus target price of $17.00, suggesting a potential upside of 189.12%. Vericel has a consensus target price of $58.40, suggesting a potential upside of 44.30%. Given Zura Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Zura Bio is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Vericel beats Zura Bio on 10 of the 16 factors compared between the two stocks.

Get Zura Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZURA vs. The Competition

Export

Metric	Zura Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$563.48M	$4.01B	$7.24B	$12.90B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-5.20	12.69	273.57	25.42
Price / Sales	N/A	1,359.79	675.05	123.41
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	2.85	16.27	12.91	6.15
Net Income	-$99.35M	-$22.72M	$3.47B	$349.01M
7 Day Performance	0.51%	-1.70%	-0.46%	-1.48%
1 Month Performance	6.52%	10.77%	6.40%	2.46%
1 Year Performance	189.66%	53.15%	24.88%	15.76%

Zura Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZURA Zura Bio	2.5455 of 5 stars	$5.88 +3.7%	$17.00 +189.1%	+180.7%	$563.48M	N/A	N/A	3
ZBIO Zenas BioPharma	2.7445 of 5 stars	$31.98 -1.1%	$45.71 +42.9%	+89.1%	$2.11B	$10M	N/A	N/A	Positive News
ADMA ADMA Biologics	3.6575 of 5 stars	$9.33 -0.6%	$18.67 +100.1%	-44.7%	$2.10B	$510.17M	13.33	530
ZYME Zymeworks	3.0539 of 5 stars	$29.67 +0.9%	$40.00 +34.8%	+121.6%	$2.09B	$105.96M	N/A	460	Analyst Forecast
NBTX Nanobiotix	1.1087 of 5 stars	$39.29 -3.3%	$37.33 -5.0%	+392.8%	$2.06B	$36.87M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZURA) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zura Bio (ZURA) Competitors

ZURA vs. ZBIO, ADMA, ZYME, NBTX, and VCEL

How does Zura Bio compare to Zenas BioPharma?

Summary

How does Zura Bio compare to ADMA Biologics?

Summary

How does Zura Bio compare to Zymeworks?

Summary

How does Zura Bio compare to Nanobiotix?

Summary

How does Zura Bio compare to Vericel?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zura Bio (ZURA) Competitors

ZURA vs. ZBIO, ADMA, ZYME, NBTX, and VCEL

How does Zura Bio compare to Zenas BioPharma?

Which has higher earnings & valuation, ZURA or ZBIO?

Which has more risk and volatility, ZURA or ZBIO?

Is ZURA or ZBIO more profitable?

Do analysts recommend ZURA or ZBIO?

Does the media refer more to ZURA or ZBIO?

Do insiders and institutionals hold more shares of ZURA or ZBIO?

Summary

How does Zura Bio compare to ADMA Biologics?

Is ADMA or ZURA more profitable?

Which has more risk & volatility, ADMA or ZURA?

Does the media favor ADMA or ZURA?

Do insiders & institutionals have more ownership in ADMA or ZURA?

Which has higher earnings & valuation, ADMA or ZURA?

Do analysts rate ADMA or ZURA?

Summary

How does Zura Bio compare to Zymeworks?

Do analysts recommend ZURA or ZYME?

Which has more volatility & risk, ZURA or ZYME?

Do institutionals and insiders hold more shares of ZURA or ZYME?

Which has better earnings and valuation, ZURA or ZYME?

Is ZURA or ZYME more profitable?

Does the media prefer ZURA or ZYME?

Summary

How does Zura Bio compare to Nanobiotix?

Which has more volatility and risk, NBTX or ZURA?

Which has better valuation & earnings, NBTX or ZURA?

Does the media favor NBTX or ZURA?

Is NBTX or ZURA more profitable?

Do analysts prefer NBTX or ZURA?

Do institutionals and insiders have more ownership in NBTX or ZURA?

Summary

How does Zura Bio compare to Vericel?

Which has more volatility & risk, ZURA or VCEL?

Which has better valuation and earnings, ZURA or VCEL?

Do institutionals and insiders have more ownership in ZURA or VCEL?

Does the media refer more to ZURA or VCEL?

Is ZURA or VCEL more profitable?

Do analysts recommend ZURA or VCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools